---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Indication questions"
description: "Indication questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names and Testing. Questions: What is Kesimpta approved for? What is the generic name of Kesimpta? What type of drug is Kesimpta (drug class)? What tests are needed before starting Kesimpta? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Indication questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Indication

<a id="kesimpta-indication"></a>

### What is Kesimpta approved for?

> “KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated 
> syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”

Source: [KESIMPTA: Prescribing information, page 2, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=2)

## Drug names

<a id="kesimpta-generic-name"></a>

### What is the generic name of Kesimpta?

> “KESIMPTA<sup>®</sup> (ofatumumab) injection, for subcutaneous use”

Source: [KESIMPTA: Prescribing information, page 1, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=1)

> “KESIMPTA (ofatumumab) injection is a sterile, preservative-free solution for subcutaneous use.”

Source: [KESIMPTA: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=8)

<a id="kesimpta-drug-class"></a>

### What type of drug is Kesimpta (drug class)?

> “KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment 
> of relapsing forms of multiple sclerosis (MS), to include clinically isolated 
> syndrome, relapsing-remitting disease, and active secondary progressive 
> disease, in adults. (1)”

Source: [KESIMPTA: Prescribing information, page 1, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=1)

> “Ofatumumab is a recombinant human monoclonal immunoglobulin G1 (IgG1) antibody that binds to human CD20 
> expressed on B-cells. Ofatumumab is produced in a murine NS0 cell line and consists of two IgG1 heavy chains and two 
> kappa light chains with a molecular weight of approximately 146 kDa.”

Source: [KESIMPTA: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=8)

## Testing

<a id="kesimpta-tests-before-starting"></a>

### What tests are needed before starting Kesimpta?

> “Before initiating KESIMPTA, screen for Hepatitis B virus (HBV) and 
> obtain serum quantitative immunoglobulins, aminotransferases, alkaline 
> phosphatase, and bilirubin. (2.1)”

Source: [KESIMPTA: Prescribing information, page 1, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=1)

> “Screen your patients for HBV, monitor Ig levels, and obtain liver function tests<sup>1</sup> Hint: HBV, Ig, and liver function testing can be added to your patient’s regular blood panels”

Source: [KESIMPTA: Starting Patients on KESIMPTA® (ofatumumab) | HCP, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/getting-started#:~:text=Screen%20your%20patients%20for%20HBV%2C,your%20patient%E2%80%99s%20regular%20blood%20panels)

<a id="kesimpta-hepatitis-b-screening"></a>

### How should patients be screened for hepatitis B before Kesimpta?

> “HBV screening should be 
> performed in all patients before initiation of treatment with KESIMPTA. At a minimum, screening should include 
> Hepatitis B surface antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) testing. These can be complemented with 
> other appropriate markers as per local guidelines. For patients who are negative for HBsAg and positive for HB core 
> antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment 
> with KESIMPTA. These patients should be monitored and managed following local medical standards to prevent HBV 
> infection or reactivation.”

Source: [KESIMPTA: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=3)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Pharmacology](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage)
